Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

被引：6
|
作者：
Shah, Jatin J. [1 ]
Feng, Lei [2 ]
Thomas, Sheeba K. [3 ]
Weber, Donna [3 ]
Wang, Michael [4 ]
Manasanch, Elisabet E. [3 ]
Mendoza, Kathleen [3 ]
Orlowski, Robert Z. [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.1540.1540
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] PHASE 1 STUDY OF THE NOVEL KINESIN SPINDLE PROTEIN INHIBITOR ARRY-520+CARFILZOMIB(CAR) IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
    Shah, J.
    Thomas, S.
    Weber, D.
    Wang, M.
    Orlowski, R.
    HAEMATOLOGICA, 2013, 98 : 243 - 243
  • [2] Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520+Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM)
    Shah, Jatin J.
    Feng, Lei
    Thomas, Sheeba K.
    Weber, Donna M.
    Wang, Michael
    Hilder, Brandi
    Alexanian, Raymond
    Orlowski, Robert Z.
    BLOOD, 2013, 122 (21)
  • [3] Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520+Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma
    Shah, Jatin J.
    Weber, Donna M.
    Thomas, Sheeba K.
    Alexanian, Raymond
    Wang, Michael
    Qazilbash, Muzaffar H.
    Parmar, Simrit
    Shah, Nina
    Bashir, Qaiser
    Popat, Uday R.
    Hilder, Brandi
    Orlowski, Robert Z.
    BLOOD, 2012, 120 (21)
  • [4] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hans C. Lee
    Jatin J. Shah
    Lei Feng
    Elisabet E. Manasanch
    Rebecca Lu
    Ashley Morphey
    Brandon Crumpton
    Krina K. Patel
    Michael L. Wang
    Raymond Alexanian
    Sheeba K. Thomas
    Donna M. Weber
    Robert Z. Orlowski
    Blood Cancer Journal, 9
  • [5] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Lu, Rebecca
    Morphey, Ashley
    Crumpton, Brandon
    Patel, Krina K.
    Wang, Michael L.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    BLOOD CANCER JOURNAL, 2019, 9 (10)
  • [6] Phase I-b study of isatuximab plus carfilzomib in relapsed and refractory multiple myeloma (RRMM).
    Chari, Ajai
    Richter, Joshua Ryan
    Shah, Nina
    Wong, Sandy Wai Kuan
    Jagannath, Sundar
    Cho, Hearn J.
    Biran, Noa
    Wolf, Jeffrey
    Parekh, Samir S.
    Munster, Pamela N.
    Madduri, Deepu
    Campana, Frank
    Martin, Thomas G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
    Hernandez-Garcia, Susana
    San-Segundo, Laura
    Gonzalez-Mendez, Lorena
    Corchete, Luis A.
    Misiewicz-Krzeminska, Irena
    Martin-Sanchez, Montserrat
    Lopez-Iglesias, Ana-Alicia
    Macarena Algarin, Esperanza
    Mogollon, Pedro
    Diaz-Tejedor, Andrea
    Paino, Teresa
    Tunquist, Brian
    Mateos, Maria-Victoria
    Gutierrez, Norma C.
    Diaz-Rodriguez, Elena
    Garayoa, Mercedes
    Ocio, Enrique M.
    HAEMATOLOGICA, 2017, 102 (12) : 2113 - 2124
  • [8] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Costa, Luciano J.
    Davies, Faith E.
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Hong, Wan-Jen
    Dail, Monique
    Salem, Ahmed Hamed
    Yang, Xiaoqing
    Masud, Abdullah A.
    Munasinghe, Wijith
    Ross, Jeremy A.
    Bueno, Orlando F.
    Kumar, Shaji K.
    Stadtmauer, Edward A.
    BLOOD ADVANCES, 2021, 5 (19) : 3748 - 3759
  • [9] Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Costa, Luciano J.
    Stadtmauer, Edward A.
    Morgan, Gareth
    Monohan, Gregory
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Mobasher, Mehrdad
    Freise, Kevin J.
    Ross, Jeremy A.
    Pesko, John
    Munasinghe, Wijith
    Gudipati, Saketh
    Mudd, Sarah
    Bueno, Orlando
    Kumar, Shaji K.
    BLOOD, 2018, 132
  • [10] Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
    Jakubowiak, Andrzej J.
    Jasielec, Jagoda K.
    Rosenbaum, Cara A.
    Cole, Craig E.
    Chari, Ajai
    Mikhael, Joseph
    Nam, Jennifer
    McIver, Amanda
    Severson, Erica
    Stephens, Leonor A.
    Tinari, Kathryn
    Rosebeck, Shaun
    Zimmerman, Todd M.
    Hycner, Tyler
    Turowski, Agata
    Karrison, Theodore
    Zonder, Jeffrey A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (04) : 549 - 560
12345